Amgen's First Quarter 2009 Adjusted Earnings Per Share Decreased 4 Percen...((R) (Epoetin alfa) increased 2 percent t...),Health
Navigation Links
Amgen's First Quarter 2009 Adjusted Earnings Per Share Decreased 4 Percent to $1.08
Date:4/23/2009
(R) (Epoetin alfa) increased 2 percent to $565 million in the first quarter of 2009 versus $554 million in the first quarter of 2008, primarily due to an increase in demand. The increase in demand is principally due to patient population growth and an increase in price, partially offset by changes in customer purchasing patterns.
Combined worldwide sales of Neulasta(R) (pegfilgrastim) and NEUPOGEN(R) (Filgrastim) decreased 1 percent to $1,073 million in the first quarter of 2009 versus $1,086 million for the first quarter of 2008. Combined sales of Neulasta and NEUPOGEN in the U.S. were $796 million in the first quarter of 2009 versus $792 million in the first quarter of 2008, an increase of 1 percent due primarily to an increase in demand slightly offset by unfavorable changes in wholesaler inventories. The increase in demand was driven by a mid single digit increase in average net sales price, partially offset by a decline in units sold. Combined international sales decreased 6 percent to $277 million in the first quarter of 2009 versus $294 million for the same quarter in the prior year. This decline is due to the negative impact of changes in foreign exchange, which aggregated approximately $29 million, partially offset by an increase in demand driven by the continued conversion from NEUPOGEN to Neulasta. Excluding the impact of foreign exchange, combined worldwide product sales of NEUPOGEN and Neulasta increased 1 percent and international product sales increased 4 percent.
Sales of Enbrel(R) (etanercept) decreased 20 percent in the first quarter to $758 million versus $951 million during the same period in 2008, driven primarily by unfavorable changes in wholesaler inventory and to a lesser extent a decline in demand. Sales of ENBREL benefited from approximately $120 million of wholesaler inventory loading due to a shift to wholesaler distribution in the first quarter of 2008. Excluding this positive impact to the fir
'/>"/>
| SOURCE Amgen Copyright©2009 PR Newswire. All rights reserved |
Related medicine news :
1. First biomarker discovered that predicts prostate cancer outcome
2. FDA Approves First Anti-Psychotic for Kids
3. Single-incision belly-button surgery to remove kidney performed first at UT Southwestern
4. First study examines newly-licensed RN work attitudes and intentions
5. Glades General Hospital First in Palm Beach County to Provide On-Site Electronic Birth Registration
6. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
7. Father and Daughter From Tanzania Receive Their First Medical Examination in Newport Beach
8. High and mighty: first common height gene identified by researchers behind obesity gene finding
9. APA Comments on FDAs First Approval of Medication to Treat Pediatric Schizophrenia and Bipolar Disorder
10. TriWest Creates First-of-its-Kind Partnership to Offer Military Leaders With Grief Support Program
11. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
Post Your Comments:
(Date:12/16/2009)... 16 For wounded U.S. servicemen ... in Washington, D.C., the holidays can be a particularly ... travel home rely more than ever on the healing ... week, calling home just got easier for Walter Reed ... cards, which will provide hundreds of minutes of holiday ...
(Date:12/16/2009)... second, possibly deadly, attack is long-term goal, researchers say ... have developed a tool to predict whether a patient ... a first stroke. , "This is an important new ... a second stroke soon after a first stroke are ... Hakan Ay, of Massachusetts General Hospital and Harvard Medical ...
(Date:12/16/2009)... In an advance that could help ease health and ... reporting development of technology for changing the behavior of ... gateway into the environment. Their study was published in ... Helen Jarvie from the UK Centre for Ecology and ... in the production of nanoparticles particles less than ...
(Date:12/16/2009)... to Quality, Cost-Effective Care , ... Washington, D.C. (Vocus) ... the best ways to rein in runaway costs while providing care ... part of the ongoing discussion includes how to ensure patients equal ... of medicine (MDs) or osteopathy (DOs). In both the House ...
(Date:12/16/2009)... Specific Neurological Stress Reduction Therapy or NSRTSM is found very ... conditions such as allergies, asthma, migraines, chronic fatigue and a ... throughout the country are using this holistic therapy including over ... ... Minneapolis, MN (Vocus) December 14, 2009 -- ...
Breaking Medicine News(10 mins):Health News:Verizon Wireless Donates $10,000 in Long-Distance Calling Cards to Soldiers at Walter Reed Hospital 2Health News:New Stroke Tool May Predict Early Recurrence 2Health News:Behavior modification could ease concerns about nanoparticles 2Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 2Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 3Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 4Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 5Health News:BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening 2Health News:BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening 3Health News:BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening 4Health News:BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening 5[0] Verizon Wireless Donates $10,000 in Long-Distance Calling Cards to Soldiers at Walter Reed Hospital[0] New Stroke Tool May Predict Early Recurrence[0] Behavior modification could ease concerns about nanoparticles[1] Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs[0] BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening
... Magnetic Navigation prominently featured on the HRS 2009 programST. ... STXS ) said today that the Heart Rhythm 2009 ... which its Niobe system is either featured or discussed ... include new efficacy data on the use of Stereotaxis, ...
... FRANCISCO, May 11 Today,s announcement takes shared responsibility ... are committing to share responsibility for saving $2 trillion ... they succeed, affordable coverage for all is within our ... coverage based on universal responsibility. We are pleased ...
... emerging pandemic of a new strain of influenza A (H1N1) ... , Researchers from the MRC Centre for Outbreak Analysis and ... World Health Organisation and public health agencies in Mexico, have ... Their key findings are as follows: , , ...
... neutral, global, multidisciplinary association of professionals involved in the lifecycle ... Career Center--a highly targeted resource for online employment connections. ... ... 11, 2009 -- The Drug Information Association (DIA) , ...
... Thermofocus(R) 5-in-1WESTON, Fla., May 11 American Scientific Resources, ... for the first quarter ending March 31, 2009. ... sales of $263,603 for the first quarter of 2009, ... first quarter of 2008.The sales increase was predominantly due ...
... Inc. (NasdaqGM: SMBL) will hold its annual meeting of stockholders ... the St. Julien Hotel (Fandango Room), 900 Walnut Street, Boulder, ... business on April 1, 2009, are entitled to attend and ... About Smart Balance, Inc. , Smart Balance, Inc. ...
Other Medicine News:Health News:Stereotaxis' Market Leadership Highlighted at Heart Rhythm 2009 2Health News:Stereotaxis' Market Leadership Highlighted at Heart Rhythm 2009 3Health News:Stereotaxis' Market Leadership Highlighted at Heart Rhythm 2009 4Health News:Swine flu: Early findings about pandemic potential reported in new study 2Health News:Drug Information Association (DIA) Launches New Online Career Center 2Health News:Drug Information Association (DIA) Launches New Online Career Center 3Health News:American Scientific Resources, Inc. Releases First Quarter Revenues 2Stereotaxis' Market Leadership Highlighted at Heart Rhythm 2009Statement by Blue Shield of California CEO Bruce Bodaken Regarding White House Health Reform AnnouncementSwine flu: Early findings about pandemic potential reported in new studyDrug Information Association (DIA) Launches New Online Career CenterAmerican Scientific Resources, Inc. Releases First Quarter RevenuesSmart Balance, Inc. to Hold Annual Meeting of Stockholders on May 20, 2009
(Date:12/16/2009)... Inc. (OTC Bulletin Board: HEWA) an online U.S. mail-order ... 12% per annum short term debt financing. The ... of $500,000, with accrued interest and principal repayable in ... interest and principal repayable in one year from its ... for any calendar month prior to December 15, 2010. ...
(Date:12/16/2009)... AVAX Technologies, Inc. (Pink Sheets: AVXT) ("AVAX" or ... a bridge loan financing (the "2009 Financing") pursuant ... (the "Agreement") with Firebird Global Master Fund, Ltd., ... a convertible promissory note, due June 30, 2010, ... issued a warrant to purchase an aggregate of ...
(Date:12/16/2009)... Inc. today announced the treatment of the first ... adhesive product, TissuGlu®. Initiation of the study marks ... the lead product toward clinical practice. ,, ... study to investigate the safety of TissuGlu and ... in abdominoplasty, or "tummy tuck," surgeries. The study ...
Breaking Medicine Technology:HealthWarehouse.com, Inc. Secures $1 Million in Debt Financing 2AVAX Technologies, Inc. Closes Bridge Financing 2AVAX Technologies, Inc. Closes Bridge Financing 3AVAX Technologies, Inc. Closes Bridge Financing 4First Patient Treated in Clinical Study of Cohera Medical's TissuGlu(R) Surgical Adhesive 2First Patient Treated in Clinical Study of Cohera Medical's TissuGlu(R) Surgical Adhesive 3Valeritas Announces Appointment of New CEO 12391 1Valeritas Announces Appointment of New CEO 12391 2Valeritas Announces Appointment of New CEO 12391 317 million US children live more than an hour away from trauma care 47486 117 million US children live more than an hour away from trauma care 47486 2Temporary infidelity may contribute to the stability of ancient relationships 8678 1... Cardiovascular, Research Foundation,s ADAPT-DES Study to Quantify Causes and Cures of ... ... Volcano Corporation,(Nasdaq: VOLC ) [TCT Booth #2013 Level 2], a ... its sponsorship of the first major study designed to,examine the role ...
... TUSTIN, Calif., Oct. 22 Peregrine,Pharmaceuticals, Inc. (Nasdaq: ... monoclonal antibodies for the treatment of cancer and,hepatitis ... has submitted a,Phase II clinical protocol with the ... study bavituximab in combination with the chemotherapy drug,docetaxel ...
Other Medicine Technology:Volcano Sponsors First Study Designed to Determine if IVUS Can Identify Patients at Risk for Stent Thrombosis and to Demonstrate the Benefit of IVUS Guidance for Procedural Outcome 2Volcano Sponsors First Study Designed to Determine if IVUS Can Identify Patients at Risk for Stent Thrombosis and to Demonstrate the Benefit of IVUS Guidance for Procedural Outcome 3Volcano Sponsors First Study Designed to Determine if IVUS Can Identify Patients at Risk for Stent Thrombosis and to Demonstrate the Benefit of IVUS Guidance for Procedural Outcome 4Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer 2Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer 3Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer 4Volcano Sponsors First Study Designed to Determine if IVUS Can Identify Patients at Risk for Stent Thrombosis and to Demonstrate the Benefit of IVUS Guidance for Procedural OutcomePeregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Standard type 1/1 (mm), opening width 8.0 mm and length 8 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 17.0 mm and length 21 mm....
The Vitek 2 is a fully automated bacteriology system that performs bacterial identification and susceptibility testing analysis using a standard inoculum. It detects resistance and helps combat bacte...
IDS Rapid Yeast Plus, a microbial identification system....
Medicine Products:| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |